Section of Transplant Immunology, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Section of Transplant Immunology, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030
J Immunol. 2018 Sep 1;201(5):1389-1399. doi: 10.4049/jimmunol.1800324. Epub 2018 Jul 18.
Proteinase 3 (P3), a serine protease expressed by myeloid cells, localized within azurophil granules, and also expressed on the cellular membrane of polymorphonuclear neutrophils (PMN), is the target of autoimmunity in granulomatosis with polyangiitis. PR1, an HLA-A2 restricted nonameric peptide derived from P3, has been targeted effectively in myeloid leukemia. We previously showed (Molldrem et al. 2003. 111: 639-647) that overexpression of P3 in chronic myeloid leukemia induces apoptosis of high-affinity PR1-specific T cells, leading to deletional tolerance and leukemia outgrowth. In this study, we investigated the effect of membrane P3 (mP3)-expressing PMN and acute myeloid leukemia (AML) blasts on the proliferation of CD4 and CD8 T cells in vitro. We demonstrate that mP3-expressing PMN significantly inhibits autologous healthy donor T cell proliferation but does not affect cytokine production in activated T cells and that this effect requires cell proximity and was abrogated by P3 blockade. This inhibition required P3 enzyme activity. However, suppression was not reversed by either the addition of catalase or the inhibition of arginase I. In addition to P3 blockade, anti-low density lipoprotein receptor-related protein 1 (LRP1) Ab also restored T cells' capacity to proliferate. Last, we show dose-dependent inhibition of T cell proliferation by mP3-expressing AML blasts. Together, our findings demonstrate a novel mechanism whereby PMN- and AML-associated mP3 inhibits T cell proliferation via direct LRP1 and mP3 interaction, and we identify P3 as a novel target to modulate immunity in myeloid leukemia and autoimmune disease.
蛋白酶 3(P3)是一种由髓样细胞表达的丝氨酸蛋白酶,定位于嗜天青颗粒内,也表达在多形核粒细胞(PMN)的细胞膜上,是肉芽肿性多血管炎的自身免疫靶标。PR1 是一种源自 P3 的 HLA-A2 限制性九肽,已在髓系白血病中得到有效靶向。我们之前的研究表明(Molldrem 等人,2003 年。111:639-647),慢性髓系白血病中 P3 的过度表达诱导高亲和力 PR1 特异性 T 细胞凋亡,导致删除性耐受和白血病生长。在这项研究中,我们研究了膜 P3(mP3)表达的 PMN 和急性髓系白血病(AML)blasts 对体外 CD4 和 CD8 T 细胞增殖的影响。我们证明,mP3 表达的 PMN 显著抑制自体健康供体 T 细胞的增殖,但不影响激活的 T 细胞中的细胞因子产生,并且这种效应需要细胞接近,并且被 P3 阻断所消除。这种抑制需要 P3 酶活性。但是,添加过氧化氢酶或抑制精氨酸酶 I 均不能逆转抑制作用。除了 P3 阻断外,抗低密度脂蛋白受体相关蛋白 1(LRP1)Ab 也恢复了 T 细胞的增殖能力。最后,我们显示 mP3 表达的 AMLblasts 以剂量依赖的方式抑制 T 细胞增殖。总之,我们的研究结果表明了一种新的机制,即 PMN 和 AML 相关的 mP3 通过直接 LRP1 和 mP3 相互作用抑制 T 细胞增殖,并且我们确定 P3 是调节髓系白血病和自身免疫性疾病免疫的新靶标。